In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Socorro EspuelasDepartment of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-7352-1523 Carmen Palomino-CanoDepartment of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-5523-4758 Carlos Torrado-SalmerónDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-4123-3367 Helga K RuizDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-2575-1233 Paloma M de la Torre-IglesiasDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-7768-0978 Santiago Torrado-SantiagoDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-3273-2615 Juan J TorradoDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-7823-1904 José María AlundaInstituto Universitario de Farmacia Industrial, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.ORCID 0000-0002-1491-8627 Sergio Alberto Sánchez GuiralesDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-0331-0499 Dolores R SerranoDepartment of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-0475-8420 Javier CarriónGroup ICPVet, Department of Animal Health, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0001-7486-4942 Funding
Spanish Ministry of Science and Innovation PID2023-148406OB-I00
6 · The paper itselfAbstract
Cutaneous leishmaniosis (CL) remains a major neglected tropical disease, with current therapies constrained by toxicity, high cost, and variable efficacy. Here, we evaluated an immunochemotherapy strategy combining topical amphotericin B (AmB) with the therapeutic DNA vaccine HisAK70 in a murine model of
Indexed as
Amphotericin BAntiprotozoal AgentsImmunotherapyLeishmania majorLeishmaniasis, CutaneousVaccines, DNAAnimalsDisease Models, AnimalFemaleInterferon-gammaInterleukin-4MiceMice, Inbred BALB CParomomycinAmphotericin BAntiprotozoal AgentsInterferon-gammaInterleukin-4ParomomycinVaccines, DNAamphotericin Bcutaneous leishmaniosisdrug repurposingHisAK70immunochemotherapyparomomycinTh1 immune responsetherapeutic vaccinetopical therapy
Identifiers
PMID42511526
PMCPMC13410688
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390